Opportunities and options for the use of protease inhibitors in a resource-poor setting: Experiences from southern India [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 1, 2007, Pages 119-121

  Kumarasamy, N ^a   Venkatesh, Kartik K ^b   Devaleenal, Bella ^a   Cecelia, Anitha ^a   Yepthomi, Tokugha ^a   Saghayam, Suneeta ^a   Solomon, Suniti ^a   Mayer, Kenneth H ^b  

^a YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^b MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANEMIA; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS; DIARRHEA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; KIDNEY FAILURE; LETTER; LIVER TOXICITY; NAUSEA; OBESITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; TREATMENT FAILURE; TUBERCULOSIS; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE; PROTEASE INHIBITORS; SOCIOECONOMIC FACTORS;

EID: 34848906877     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318074efac     Document Type: Letter

References (8)

1. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach - 2003 revision. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision 2003en.pdf. Accessed December 30, 2006.
2. Yazdanpanah Y, Sissoko D, Egger M, et al. Clinical efficacy of antiretroviral combination therapy on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trails. BMJ. 2004;328:249-255.
3. Carr A, Samras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
4. Kumarasamy N, Solomon S, Chaguturu SK, et al. The safety, tolerability, and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003;17:2265-2271.
5. Gray A, Abdool Karim SS, Gengiah TN. Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings. AIDS. 2006;20:302-303.
6. Kumarasamy N. Can we reduce morbidity and mortality due to HIV and stop transmission in India? Indian J Med Res. 2005;122:461-463.
7. Kumarasamy N. Generic antiretroviral drugs - will they be the answer to HIV in the developing world? Lancet. 2004;364:3-4.
8. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr. 2006;41:53-58.